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Abstract
Background: Leiomyosarcoma of the uterus is an extremely rare but highly aggressive tumor that accounts for
only 1–2 % of uterine malignancies, and is usually associated with a dismal outcome.
Case presentation: The authors present an unusual case of pedunculated subserosal leiomyosarcoma of the uterus
mimicking ovarian carcinoma. A 57-year-old postmenopausal woman presented with progressive low abdominal
pain and urinary frequency. Pelvic magnetic resonance imaging revealed a large adnexal mass with carcinomatosis
peritonei. Laboratory examination revealed an elevated serum CA-125 level (398.4 U/ml). The patient underwent
exploratory laparotomy under suspicion of ovarian malignancy. Frozen section indicated malignancy originating
from the uterus, and thus, total abdominal hysterectomy, bilateral salpingo-oophorectomy, omentectomy, pelvic
and para-aortic lymph node dissection, and mass excision were performed. Subsequent histopathologic examination
resulted in a final diagnosis of leiomyosarcoma of the uterus. The patient’s postoperative course was uneventful, and
gemcitabine and docetaxel adjuvant chemotherapy was administered.
Conclusion: The authors report an unusual case of pedunculated subserosal leiomyosarcoma of the uterus mimicking
ovarian carcinoma.
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Background
Uterine leiomyosarcoma (LMS) is a rare uterine malig-
nancy that accounts for approximately 1–2 % of uterine
malignancies and 25–36 % of uterine sarcomas. It occurs
mainly after menopause (mean age at diagnosis is 60 years
[1]) and usually presents as abnormal uterine bleeding [2].
LMS is highly aggressive tumor with a poor prognosis; a
review of the literature showed that recurrence rates range
from 45 to 73 % and 5-year overall survival rates between
30 and 42 % [3]. Here, we report an unusual case of pe-
dunculated subserosal leiomyosarcoma of the uterus mim-
icking ovarian carcinoma, and describe its imaging
findings in a postmenopausal woman.
Case presentation
A 57-year-old postmenopausal woman presented with
progressive low abdominal pain and urinary frequency
of 4 months duration. The patient had no significant
gynecological, medical, surgical, or family history, and
had no associated bowel complaints. Physical examin-
ation revealed an enlarged, relatively nodular pelvic
mass, and pelvic ultrasonography and magnetic reson-
ance imaging (MRI) depicted a large, complex, adnexal
mass, suggestive of ovarian carcinoma. Axial T2-
weighted imaging showed a solid, cystic mass with het-
erogeneous signal intensity in the pelvic cavity.
Contrast-enhanced fat-suppressed T1-weighted imaging
showed heterogeneously marked enhancement of the
mass. On sagittal and coronal T2-weighted images, the
mass abutted the uterus (Fig. 1). Ascites and omental
smudging were suspected to be due to carcinomatosis
peritonei. There was no significant lymphadenopathy.
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Laboratory examination revealed a raised serum tumor
marker (CA-125, 398.4 U/ml) level. Urinalysis results
were normal. At this juncture, based on imaging findings
and the elevated serum tumor marker level, an ovarian
malignancy was suspected.
The patient underwent exploratory laparotomy under
suspicion of ovarian malignancy. A huge pedunculated
subserosal mass arising from the uterine fundus in the cul-
de-sac was confirmed that was bilobal rather than bilateral,
and. The mass was adherent to omentum and rectosig-
moid. Both ovaries were normal in size and contour
(Fig. 2), and there was moderate amount of ascites. A por-
tion of the mass was sent for frozen section, which re-
vealed malignancy originating from the uterus. Total
abdominal hysterectomy, bilateral salpingo-oophorectomy,
omentectomy, pelvic and para-aortic lymph node dissec-
tion, and excision of a metastatic mesenteric mass of
diameter 3.0 cm were performed. The cut tumor surface
was soft, necrotic, and hemorrhagic with myxoid changes
(Fig. 2), and the omentum showed multiple brown-white
solid nodules. Microscopically, the tumor was composed
of highly atypical spindle cells with brisk mitotic activity
(≥28/10 high-power fields) and necrosis (Fig. 3). Omentum
and mesentery around the rectosigmoid showed metastatic
disease, confirming stage III disease. Pelvic and para-aortic
lymph nodes were free from tumor cells, and peritoneal
washings were negative for malignant cells. Immunohisto-
chemical staining showed tumor cells were positive for
smooth muscle actin (SMA), desmin, and h-caldesmon,
and negative for CD10, ER, PR, inhibin, and PanCK (Fig. 4).
Her postoperative course was uneventful. Gemcitabine
and docetaxel adjuvant chemotherapy was administered
and serum CA-125 decreased to normal at 1 month after
surgery. No recurrence occurred over 17 months of post-
operative follow-up.
Discussion
Leiomyosarcoma (LMS) of the uterus is an extremely rare
but highly aggressive tumor and is associated with poor
prognoses, even for early-stage disease. LMS is usually a
large, yellow or tan solitary myometrial mass with some
hemorrhagic and necrotic areas. Necrosis, moderate-to-
severe cytologic atypia, and > 15 mitotic figures per 10
high power fields (HPF) are considered typical histopatho-
logic criteria. It may be near impossible to differentiate be-
nign and malignant uterine tumors; however, pathological
features, such as, larger tumor cells, fewer stromal fibers,
increased mitotic activity, and nuclear pleomorphism may
aid differentiation. Nevertheless, the presence of mitoses





Fig. 1 Pelvic magnetic resonance image of the pedunculated subserosal leiomyosarcoma of the uterus. a Axial T2-weighted image showing a large
pelvic mass (arrows) with heterogeneous signal intensity. b Contrast-enhanced fat-suppressed T1-weighted image showing marked heterogeneous
enhancement (arrow) of the mass. c, d On sagittal (c) and coronal (d) T2-weighted images, the mass (arrows) abutted the uterus (U). Note the bridging
vessels (arrowheads) between the uterus and the juxta-uterine mass
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The signs and symptoms of LMS are similar to those
of benign leiomyoma. Presenting symptoms are nonspe-
cific and include abnormal vaginal bleeding (also a com-
mon presentation of uterine sarcoma), abdominal pain,
vaginal discharge, urinary frequency, constipation, and
abdominal distention. However, in our case, the patient
had no complaint of vaginal bleeding possibly because of
an unusual subserosal location.
Serum CA125 levels are occasionally elevated in LMS.
It has been reported preoperative serum CA125 levels
are significantly higher in LMS than in uterine leio-
myoma [4]. Although the cause of this elevation has not
been determined, Duk et al. suggested that CA125
elevation in LMS is probably caused by irritation of epi-
thelial surfaces by tumor cells rather than by tumor tis-
sues per se [5]. In our case, serum CA-125 was
considerably elevated (398.4 U/ml and given the pres-
ence of an adnexal mass, a diagnosis of primary ovarian
carcinoma was made.
MRI is very useful for determining anatomic features,
such as, the locations, sizes, and numbers of pelvic
masses. In addition, MRI may provide diagnostic infor-
mation that supports a preoperative presumption of leio-
myosarcoma; however, it is not entirely accurate. LMS
usually manifests as a large infiltrating myometrial mass
with high signal intensity on T2W images and low ADC






Fig. 2 a Gross appearance of pedunculated subserosal leiomyosarcoma of the uterus. The mass was bilobed rather than bilateral. Both ovaries
were normal in appearance. b Cut section of the uterus and tumor
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values. Final diagnosis of uterine leiomyosarcoma is
made by histopathological findings. In our case, an in-
correct initial diagnosis of ovarian malignancy was made
because ovarian cancer is more common in postmeno-
pausal women and MRI showed a large, adnexal mass,
ascites, omental smudging, and misty mesentery.
Pedunculated masses may have obscure origins and be
misinterpreted as ovarian masses. The detection of a
vascular pedicle can provide information on the origin
of a mass. When normal ovaries are visualized separ-
ately, a mass of ovarian origin can be excluded. In our
case, we retrospectively analyzed MR images, and noted
bridging vessels between the uterus and a juxta-uterine
mass, suggesting a pedunculated subserosal uterine
mass. However, normal ovaries were not visualized be-
cause ovaries were atrophied and obscured by the mass.
Several case reports have been issued on uterine masses
considered preoperatively to be ovarian tumors, due to
similar locations and imaging findings. For example, a
large pedunculated leiomyoma with cystic degeneration
mimicking ovarian malignancy [6], and an unusual huge,
multiseptated, pedunculated pyomyoma occupying the
entire abdomen that was initially misdiagnosed as ovar-
ian cancer based on imaging findings have been reported
[7]. Furthermore, in postmenopausal women, uterine
leiomyoma with hemorrhagic cystic degeneration mim-
icking ovarian malignancy [8] and leiomyosarcoma of
the rectum mimicking primary ovarian carcinoma with
normal serum marker levels and no rectal bleeding [9]
have been reported. However, few reports have been is-
sued on pedunculated subserosal leiomyosarcoma of the
uterus simulating ovarian carcinoma in terms of ana-
tomic location, imaging findings, or serum tumor
marker level.
Immunohistochemistry may be helpful for differentiat-
ing leiomyosarcoma from other tumors. In our case, im-
munohistochemistry revealed diffuse strong positivity for
smooth muscle actin (SMA), desmin and h-caldesmon,
and SMA and desmin are usually expressed in LMS,
whereas h-caldesmon is highly specific for LMS [10].
Total hysterectomy and bilateral salpingo-oophorectomy
are recommended for LMS grossly confined to the uterus,
but dissection of pelvic and para-aortal lymph nodes is not
routinely recommended. Lymphatic spread is not common
and lymph node involvement is only encountered in <3 %
[11]. However, the presence of metastatic disease indicates
the need for complete surgical cytoreduction. Furthermore,
lymphadenectomy should be performed in patients with
suspicious metastatic nodes or extrauterine disease. None-
theless, despite aggressive cytoreductive surgery, intraperi-
toneal recurrence or distant metastasis occurs in >50 % of
cases [12].
LMS is characterized by early dissemination and me-
tastases to multiple organs and primarily presents with
hematogenous spread. Interestingly, in the described
case, metastases occurred to omentum and mesentery
around the rectosigmoid via direct peritoneal spread from
the pedunculated subserosal leiomyosarcoma. Prognosis
primarily depends on the extent of disease at diagnosis and
mitotic index. In addition, several authors have suggested
that tumor size may be an important prognostic factor [2,
13]. Garcia et al. [3] reported rates of recurrence or pro-
gressive disease of 76 and 85 % for stage I and stages II–IV,
respectively, and overall survivals for stage I of 64 and 38 %
at 3 and 5 years (overall survival was 30 % for stages II–IV).
Although the role of adjuvant chemotherapy is unclear, pa-
tients with advanced-stage disease are recommended for
gemcitabine and docetaxel adjuvant chemotherapy, for
which the response rate is around 36 % [14, 15].
Conclusion
In summary, we present an unusual case of pedunculated
subserosal leiomyosarcoma of the uterus that mimicked
ovarian malignancy, based on anatomic location, imaging
findings, and serum tumor marker level, in a postmeno-
pausal woman. This case cautions pedunculated subserosal
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Fig. 4 Immunohistochemistry revealed diffuse strong positivity for SMA (a), desmin (b), and h-caldesmon (c) (×400). SMA: smooth muscle actin
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leiomyosarcoma of the uterus with a highly elevated serum
CA-125 marker may mimic ovarian carcinoma and should
be considered in the differential diagnosis of an adnexal
mass in postmenopausal women.
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